COCH

EX-99.1

2 ea031082201ex99-1.htm

PRESS RELEASE DATED NOVEMBER 5, 2026

Exhibit 99.1

Envoy Medical Reports Third Quarter 2026 Results and Highlights Continued Progress

Company Reaches Six-Month Milestone in Pivotal

Trial of Fully Implanted Cochlear Implant

Second Module of Modular PMA Application Submitted to FDA Following Quarter End

White Bear Lake, Minnesota—November 5, 2026 - Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today reported financial results for the third quarter ended September 30, 2026, and provided a business update, highlighting continued execution on its corporate initiatives.

“We continued to make significant progress with our investigational fully implanted cochlear implant during the third quarter, as we approach an extremely exciting 2027,” said Brent Lucas, Chief Executive Officer of Envoy Medical. “Not only did we report encouraging 12-month data from the first 10 participants in our trial, but we also surpassed the three-month follow-up mark for the full cohort. Since quarter end, we have now surpassed the six-month follow-up milestone. We remain on track for all participants to complete their 12-month visits by early in the second quarter of 2027. Each milestone brings us closer to offering cochlear implant candidates a fully implanted option they have wanted for decades.”

Corporate and Financial Highlights for Q3 2026:

●Positive 12-Month Data Showed Continued Improvement in Speech Perception. The Company reported positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial of the investigational fully implanted Acclaim® cochlear implant. These participants achieved a mean Consonant-Nucleus-Consonant (“CNC”) word recognition score of 53.2% at their 12-month visits, compared to a pre-implantation baseline of 15.2%, a 38.0 percentage point improvement and continued gains from the 24.0 percentage point improvement reported at six months. The trial’s primary efficacy endpoint will be evaluated based on 12-month data.

●Three-Month Follow-Up Window Completed for Full Cohort. The Company announced that its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant passed the three-month follow-up window, marking another key clinical milestone as the Company advances the study toward its primary efficacy endpoint, which will be evaluated on 12-month data.

●Expanded Global Intellectual Property Portfolio. The Company was granted Canadian and Hong Kong patents relating to implantable cochlear system design and middle ear sensor signal processing, expanding its global portfolio to 97 granted patents, consisting of 40 U.S. and 57 foreign patents, with an additional 35 applications pending.

Highlights Subsequent to Q3 2026:

●Second Module of Modular PMA Application Submitted to the FDA. The Company submitted the second module of its Modular Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for its Breakthrough Device-designated investigational Acclaim® cochlear implant. The Company expects to submit a total of four modules, with the final module containing final clinical trial data. The Company expects all Stage 2 participants to complete 12-month data collection by early in the second quarter of 2027, with submission of the final module planned to follow a few months thereafter.

●Six-Month Follow-Up Visit Milestone Surpassed. The Company announced that its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant surpassed the six-month follow-up visit milestone for all 56 patients. To the Company’s knowledge, Envoy Medical is the first company to reach this milestone in a U.S. pivotal clinical trial of a fully implanted cochlear implant. The trial’s primary efficacy endpoint will be evaluated based on 12-month data.

●Atlas Litigation Dismissed. On October 6, 2026, the Company entered into a dismissal agreement with Atlas Merchant Capital SPAC Fund I LP, under which all claims asserted by Atlas in the litigation filed in the Delaware Court of Chancery were dismissed with prejudice, and the litigation was terminated without any payment by the Company or the other defendants.

Financial Results for the Quarter Ended September 30, 2026 (dollars in thousands):

Net revenue was $66 for the three months ended September 30, 2026, compared to $42 for the three months ended September 30, 2025.

Cost of goods sold for the three months ended September 30, 2026, was $244, compared to $203 for the three months ended September 30, 2025.

R&D expenses for the three months ended September 30, 2026, were $3,077 compared to $2,700 for the three months ended September 30, 2025. This increase of $377 mainly reflects additional clinical trial follow-up activity following completion of enrollment in the first quarter of 2026 and higher costs

EX-99.1

2 ea030137201ex99-1.htm

PRESS RELEASE DATED AUGUST 10, 2026

Exhibit 99.1

Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones

Submitted First Module of Modular PMA Application to FDA

Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement in Speech Perception

White Bear Lake, Minnesota--(Newsfile Corp. – August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health company pioneering fully implanted hearing solutions, today reported financial results for the second quarter ended June 30, 2026, and provided a business update, highlighting continued execution on its corporate initiatives.

“The second quarter moved us measurably closer to bringing our fully implanted cochlear implant to market,” said Brent Lucas, Chief Executive Officer of Envoy Medical. “We submitted the first of four modules of our modular PMA application and our pivotal clinical trial continued to advance. We expect to submit the remaining modules on a rolling basis, with the fourth and final module targeted during the second quarter of 2027. Since quarter end, we reported 12-month data on the first 10 participants in Stage 1 and the full trial surpassed the three-month follow-up mark. We remain focused on the successful and timely execution of our clinical trial but continue to lay the operational groundwork for an exciting future with tremendous value creation potential. Should we receive approval to market our device, we believe that the demand will be substantial and we want to be prepared to support that demand quickly and with tremendous success.”

Corporate and Financial Highlights for Q2 2026:

●First Module of Modular PMA Application Submitted to the FDA. The Company submitted the first module of its Modular Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for its Breakthrough Device-designated investigational Acclaim® cochlear implant. Unlike a traditional PMA, the modular pathway allows the Company to submit completed sections for review as they become available, enabling earlier FDA engagement, iterative feedback, and a defined cadence of milestones. The Company expects to submit a total of four modules, with the final module containing final clinical trial data targeted for submission in the second quarter of 2027.

●Expanded Intellectual Property Portfolio. The Australian and European patent offices granted the Company four patents relating to important innovations in implantable system design, signal analysis, and battery recharge safety, further strengthening the Company’s intellectual property position in the implantable medical device and cochlear implant industries.

●At-the-Market (ATM) Equity Facility Terminated. The Company terminated its ATM equity offering program, under which it was previously authorized to offer and sell up to $15 million of its common stock.

Highlights Subsequent to Q2 2026:

●Positive 12-Month Data Showed Continued Improvement in Speech Perception. The Company reported positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial of the investigational fully implanted Acclaim® cochlear implant. These participants achieved a mean Consonant-Nucleus-Consonant (“CNC”) word recognition score of 53.2% at their 12-month visits, compared to a pre-implantation baseline of 15.2%, a 38.0 percentage point improvement and continued gains from the 24.0 percentage point improvement reported at six months. The trial’s primary efficacy endpoint will be evaluated based on 12-month data.

●Three-Month Follow-Up Window Completed for Full Cohort. The Company announced that its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant passed the three-month follow-up window, marking another key clinical milestone as the Company advances the study toward its primary efficacy endpoint, which will be evaluated on 12-month data.

Financial Results for the Quarter Ended June 30, 2026 (dollars in thousands):

Net revenue was $51 for the three months ended June 30, 2026.

Cost of goods sold for the three months ended June 30, 2026, was $278, compared to $234 for the three months ended June 30, 2025.

R&D expenses for the three months ended June 30, 2026, were $3,132 compared to $2,485 for the three months ended June 30, 2025. This increase of $647 mainly reflects additional clinical trial follow-up activity as a result of the clinical trial being fully enrolled, fees related to the submission of the first module of the Company’s PMA application, and personnel costs related to the clinical trial.

Sales and marketing expenses for the three months ended June 30, 2026, were $181 compared to $361 for the three months ended June 30, 2025. The decrease of $180 is primarily due to the reallocation of resources to research and development activities in support o

EX-99.1

2 ea028996501ex99-1.htm

PRESS RELEASE DATED MARCH 11, 2026

Exhibit 99.1

Envoy Medical Reports Landmark Accomplishments, Advancing Toward

FDA Approval of First-Of-Its-Kind Fully Implanted Cochlear Implant

Company Completes Historic Trial Enrollment, Secures Transformational Financing, and

Sees Promising Early Clinical Data Presented at Industry Conferences

White Bear Lake, Minnesota – May 11, 2026 – Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant.

“The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted by the completion of enrollment in our pivotal clinical trial and the successful execution of a significant financing,” said Brent Lucas, Chief Executive Officer of Envoy Medical. “Achieving full enrollment in our pivotal clinical study represents a critical step. We continue to be encouraged by the trial’s progress and remain focused on advancing toward PMA submission and, ultimately, commercialization. With a substantially strengthened balance sheet and the support of leading healthcare investors, we believe we are well positioned to execute on our strategic objectives and deliver on the roadmap ahead.”

Corporate and Financial Highlights for Q1 2026:

●Pivotal Trial Enrollment Complete — A First for the Industry

In a defining milestone for the hearing health sector, Envoy Medical became the first cochlear implant company to achieve full enrollment of a U.S. pivotal clinical trial evaluating a fully implanted cochlear implant seeking FDA approval. The 56th and final patient was successfully implanted on March 11, 2026, completing enrollment across U.S. sites. The Company is now collecting 12-month follow-up data from all participants, with a Premarket Approval (PMA) submission to the FDA to follow.

●Transformational Capital Raise

Envoy Medical closed an upsized public offering for up to $78.0 million, including $30.0 million in gross proceeds at closing with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants. The financing was led by Nantahala Capital and included healthcare-dedicated funds such as Broadfin Holdings, as well as existing shareholders including members of the Board and management team.

●Expanded Intellectual Property Portfolio

As of February 20, 2026, Envoy Medical has expanded its global IP portfolio to 47 patents across North America, Europe, Asia, and Australia. In February alone, the Company secured three new patents strengthening its competitive position in the fully implanted hearing space.

Highlights Subsequent to Q1 2026:

●Promising Early Clinical Data Presented

Interim six-month clinical data from the first 10 patients

in the pivotal study showed no study-defined serious adverse events, mean CNC word recognition improved from 15.2% to 39.2%, median daily device wear time of 24 hours, and improvements in quality-of-life and tinnitus scores. Initial safety and performance data for these 10 patients were presented at the American Academy of Audiology Annual Conference and the Combined Otolaryngology Spring Meetings.

●All 56 Pivotal Trial Patients Activated

Following the completion of enrollment, Envoy Medical confirmed that all 56 patients implanted in the pivotal clinical trial have been activated. This milestone validates that the full patient cohort is progressing through the study protocol on schedule, keeping the Company on track to collect the 12-month endpoint data required for its planned PMA submission to the FDA.

●Board Strengthened

Envoy Medical appointed medical device veteran Chas McKhann to its Board of Directors in April 2026, further enhancing the Company’s expertise as it prepares to conclude its pivotal clinical study and prepare for commercial launch.

●First Patients Reach 12-Month Endpoint

The first three patients implanted in the pivotal trial successfully completed their 12-month endpoint visit, marking a key milestone in the study’s progress. The primary endpoints for the trial are tied to 12-month data, and achieving this critical milestone on schedule underscores the Company’s continued execution as it steadily marches toward PMA submission and commercialization.

Financial Results for the Quarter Ended March 31, 2026 (dollars in thousands):

Net Revenue was $39 for the three months ended March 31, 2026.

Cost of goods sold for the three months ended March 31, 2026, were $313, compared to $226. The $87 increase is primarily due to higher scrap and materials usage as well as increased fees for third-parties performing work related to our products.

R&D expenses for the three months ended March 31, 2026, were $3,642 compared to $2,748 for the three month